Key Drivers
- Non-cash profit
- Negative cash flow
- Balance-sheet strain
AIAI Summary
OMER has finally moved from pure pre-revenue biotech to an early commercialization story thanks to YARTEMLEA and the coming permanent J-code, but with negative equity, $310.6M debt, and negative operating/free cash flow, the stock remains a high-risk re-rating only if adoption proves it can convert into real cash generation.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Non-cash profit
- •Negative cash flow
- •Balance-sheet strain
OMER's quarter showed a sharp accounting profit on tiny revenue, but persistent cash burn, negative equity, and heavy leverage mean the apparent turnaround is not yet financially durable. క
Price Behavior
Key Price Behavior Insights:
- •Failed breakout
- •Trend reversal
- •Key support test
OMER's rally to $15.06 failed, and the drop to $12.25 has flipped the short-term trend bearish, leaving $13.26-$13.53 as resistance and $11.84-$11.38 as key support.
Ran from the low-$13s to $15.06, then sharply reversed to $12.25
Sentiment & News
Key News Insights:
- •Launch traction
- •Profit surprise
- •Early rollout
Omeros' Q1 results highlighted a strong early U.S. launch of YARTEMLEA, with $9.9M in net sales and $56.1M in net income, signaling momentum for its newly approved TA-TMA treatment.
The early commercial performance is a positive catalyst for Omeros, but investor focus will now shift to whether YARTEMLEA can sustain and scale sales growth
Similar Companies in Healthcare
Other companies in the same sector with AI ratings